Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
Dupixent Markets Largely Untapped
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.
